FindTrial
Sign In

KITE-753

DRUG5 trials

Sponsors

Kite Pharma Inc., Kite, A Gilead Company, M.D. Anderson Cancer Center

Conditions

B-cell Acute Lymphoblastic LeukemiaRelapsed and/or Refractory B-cell LymphomaRelapsed or Refractory Large B-cell LymphomaRelapsed or refractory large B-cell lymphoma (r/r LBCL)Solid and Hematological Malignancies

Phase 1

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
RecruitingNCT04989803
Kite, A Gilead CompanyRelapsed and/or Refractory B-cell Lymphoma
Start: 2021-10-27End: 2030-02-01Target: 247Updated: 2026-06-29
Phase 1 Study Of KITE-753 in R/R B-Cell ALL
Not yet recruitingNCT07674823
M.D. Anderson Cancer CenterB-cell Acute Lymphoblastic Leukemia
Start: 2026-12-31End: 2031-04-01Target: 18Updated: 2026-06-30

Phase 3

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
RecruitingNCT07479797
Kite, A Gilead CompanyRelapsed or Refractory Large B-cell Lymphoma
Start: 2026-05-22End: 2031-05-01Target: 550Updated: 2026-07-15
A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants with Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
Not yet recruitingCTIS2025-524403-80-00
Kite Pharma Inc.Relapsed or refractory large B-cell lymphoma (r/r LBCL)
Target: 156Updated: 2026-07-17

Unknown Phase

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Enrolling by invitationNCT05041309
Kite, A Gilead CompanySolid and Hematological Malignancies
Start: 2021-12-15End: 2040-12-01Target: 1000Updated: 2026-05-14

Related Papers

KITE-753: A phase 2 study of an autologous anti-CD19/CD20 CAR T-cell therapy in CAR-naive patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Journal of Clinical Oncology2026-05-28
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2
Journal of Hematology & Oncology2026-04-27
A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
Journal of Clinical Oncology2025-05-281 citations
Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
Blood2024-11-056 citations
KITE-753: An Autologous Rapid Manufactured Anti-CD19/CD20 CAR-T Product for the Treatment of B-Cell Malignancies
Blood2024-11-051 citations
KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).
Journal of Clinical Oncology2022-06-013 citations